Hip Resurfacing Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

Hip resurfacing arthroplasty (HRA) is a bone-conserving alternative to total hip replacement that removes only the arthritic surface of the femoral head and lines it with a metal cap, while the acetabulum receives a metal cup with a matching bearing surface. Unlike conventional total hip replacement, where the femoral head and neck are removed and a long stem is inserted into the femoral canal, hip resurfacing preserves the femoral head, neck, and proximal femoral bone stock. This preservation is of significant value in young, active patients for whom future revision surgery — should it ever be needed — is technically much easier with intact proximal femoral anatomy.

The most widely studied and registered implant is the Birmingham Hip Resurfacing (BHR) system (Smith+Nephew), introduced in 1997. Registry data from the UK, Australia, and Sweden demonstrate 95%+ survival in appropriately selected male patients at 10 years. However, gender is a critical selection variable: women, patients with small femoral heads (<46 mm), patients with hip dysplasia, and those with compromised bone quality (osteoporosis, renal disease) have significantly higher failure rates due to greater metal ion sensitivity, edge loading, and a higher incidence of adverse local tissue reactions (ALTR) including pseudotumours and metallosis.

Hip resurfacing uses a metal-on-metal (MoM) bearing surface, generating cobalt and chromium ions from bearing contact and fretting corrosion at the head-stem taper. Modern regulatory guidance from the MHRA (UK) and FDA requires annual blood metal ion monitoring in all MoM hip patients and follow-up cross-sectional imaging (MARS MRI) if ions are elevated or symptoms develop. Despite these surveillance requirements, well-selected and well-monitored patients with HRA report exceptional activity levels, high satisfaction, and lower dislocation rates than conventional THA owing to the large-diameter head (typically 44–58 mm).

• Primary hip osteoarthritis in young active males — the core indication; patients under 60 with advanced OA (Tönnis Grade 2–3) who wish to maintain high activity levels and want to preserve bone stock for potential future revision
• Post-traumatic hip arthritis — secondary arthritis after acetabular fractures or hip dislocation in young patients with intact femoral head anatomy
• Hip dysplasia with secondary arthritis — selected cases with adequate acetabular coverage; combined with PAO in borderline cases
• Avascular necrosis (AVN) of the femoral head (early stages) — Stage 1–2 AVN in young patients before collapse; resurfacing is used with caution as necrotic bone under the cap risks component subsidence
• Ankylosing spondylitis with hip involvement — end-stage inflammatory arthropathy in young patients requiring bone preservation for long-term planning
• Childhood hip conditions with secondary arthritis — including Legg-Calvé-Perthes disease and slipped capital femoral epiphysis leading to early adult arthritis

Ideal candidates for hip resurfacing are typically active males under 60 with large femoral heads (>50 mm measured on pre-operative templating), good bone quality (normal DXA T-score), radiographically confirmed advanced hip arthritis, and no large cysts in the femoral head or neck that would compromise the bone-implant interface. These patients must understand and accept the lifelong metal ion monitoring requirements.

Favourable characteristics:

• Male sex (significantly lower failure rates than females)
• Age under 60
• Femoral head diameter >50 mm (larger heads generate lower metal ion levels)
• Good bone quality (T-score > −1.0)
• High activity demands — patient wishes to return to running, cycling, or competitive sport
• Small or no femoral head cysts (<1 cm)

Contraindications:

• Female sex — 2–3× higher failure rate; metal ion sensitivity; smaller femoral heads; most registries recommend total hip replacement rather than resurfacing for women
• Renal impairment — reduces cobalt and chromium clearance, raising systemic metal ion levels
• Known metal hypersensitivity — cobalt, chromium, or nickel allergy is a firm contraindication
• Avascular necrosis (Stage 3–4) — collapsed or fragmented femoral head cannot support the metal cap
• Osteoporosis (T-score < −2.5) — risk of femoral neck fracture under the cap
• Large femoral head cysts (>1 cm) — inadequate bone-implant contact
• Obesity (BMI >35) — increased edge loading, ion generation, and soft tissue reaction risk
• Pre-existing hepatic disease — impaired cobalt metabolism

Surgical approach: Hip resurfacing is most commonly performed via a posterior approach with hip dislocation, which provides the exposure needed to prepare both the femoral head and acetabulum. Some experienced surgeons use a modified anterolateral or direct anterior approach to further reduce muscle damage. The procedure is technically more demanding than standard THA, requiring precise femoral head preparation, accurate guide pin placement in neutral-to-slight valgus (135° stem-shaft angle target), and meticulous reaming to avoid notching the femoral neck.

Femoral preparation: The femoral head is sized and prepared using a stepped reaming system. A guide pin is inserted under fluoroscopic guidance at the planned angle. The femoral head surface is milled to accept the metal cap; the neck is preserved entirely. The implant is typically cemented onto the femoral head using low-viscosity bone cement.

Acetabular preparation: The acetabulum is reamed to the appropriate size and the metal shell press-fitted into the prepared bone (cementless fixation). Inclination (target 40° ± 5°) and anteversion (15° ± 5°) are critical for reducing edge loading and metal ion generation. Fluoroscopic and/or robotic guidance improves component positioning accuracy.

Available implant systems:

• Birmingham Hip Resurfacing (BHR) — Smith+Nephew; most extensively registered; best long-term outcome data; cobalt-chromium alloy; cement femoral + cementless acetabular
• Conserve Plus — Wright Medical; similar design; available with cement or press-fit femoral fixation
• Cormet Hip Resurfacing System — Corin Group; thinner acetabular cup; similar clinical performance
• ICON Hip Resurfacing — Biomet; features a porous-coated femoral component as an alternative to cement fixation

Component size and metal ion levels: Research has clearly established an inverse relationship between femoral head size and serum metal ion levels. Heads of 44–46 mm generate significantly higher ion levels than 52–56 mm heads. This is the primary mechanistic reason why women (typically smaller femoral heads) have worse outcomes than men in hip resurfacing registries.

In appropriately selected patients — particularly active males under 60 — hip resurfacing offers several advantages over conventional total hip replacement:

• Bone stock preservation: The intact proximal femur allows easier and less technically complex revision surgery if needed; the entire femoral canal remains available for revision stems
• Low dislocation rate: The large-diameter femoral head (44–58 mm) dramatically reduces dislocation risk to <0.5% vs. 1–2% with standard 32–36 mm THA heads; particular advantage for patients who cannot comply with hip precautions
• Higher activity levels: Patients report higher UCLA activity scores and return-to-sport rates compared with THA; long-distance running, skiing, and contact sports have been reported in published case series
• Natural hip biomechanics: Preservation of femoral head size, neck length, and proximal femur maintains normal lever arm lengths and muscle attachment points, contributing to excellent proprioception and functional recovery
• Implant survival (males): BHR in men shows 95–97% survival at 10 years and 90–93% at 15 years per UK NJR and AOANJRR data
• Patient-reported satisfaction: Oxford Hip Score and Harris Hip Score improvements are comparable to THA; activity-related scores (UCLA Activity Score) often exceed THA counterparts in young active patients

Hip resurfacing carries the standard risks of hip arthroplasty plus specific risks related to the metal-on-metal bearing surface:

• Femoral neck fracture: The most specific complication of resurfacing; occurs in 0.5–1.5% in the early post-operative period; caused by notching the femoral neck during preparation, varus component positioning, or unprotected early loading; catastrophic but manageable with conversion to THA
• Adverse local tissue reaction (ALTR) / pseudotumour: Cobalt and chromium metal ions trigger a delayed hypersensitivity or cytotoxic reaction forming fluid-filled or solid pseudotumours around the hip; incidence 1–5% with modern BHR in ideal candidates; higher in women, patients with elevated ions, or malpositioned components; requires MRI surveillance and often revision surgery
• Elevated systemic metal ions: Serum cobalt and chromium levels above threshold (MDA guidelines: cobalt >119 nmol/L or chromium >134.5 nmol/L) require urgent clinical review; systemic cobaltism can affect cardiac rhythm, thyroid function, and vision in severe cases
• Component malpositioning: Cup inclination >55° dramatically increases edge loading and ion generation; requires meticulous surgical technique and ideally robotic or navigation assistance
• Osteolysis and aseptic loosening: Metal particle-induced bone loss leading to late component failure; less common than with older metal-on-polyethylene implants but still occurs
• Avascular necrosis of the femoral head (post-operative): Surgical devascularisation during posterior approach; incidence <1% with careful technique
• Standard arthroplasty risks: DVT/PE (prophylaxis essential), PJI (<1%), nerve injury (<0.5%), leg length discrepancy

Hospital stay (Days 1–4): Mobilisation begins on the day of or after surgery with a physiotherapist. Partial weight-bearing with crutches is standard for the first 6 weeks; some centres permit immediate full weight-bearing with uncemented femoral components. Blood metal ion baseline samples are drawn before discharge.

Early recovery (Weeks 1–8): Crutches used for 6 weeks minimum; no hip precautions equivalent to posterior THA are needed due to the large head, but patients are counselled to avoid extreme ranges of motion until soft tissue healing is confirmed. Outpatient physiotherapy focuses on hip abductor and rotator strengthening.

Intermediate recovery (Weeks 6–16): Progressive return to low-impact exercise: cycling (stationary bike at 6 weeks, road cycling at 3 months), swimming (once wound healed at 6–8 weeks), hiking. Return to sedentary work at 6–10 weeks; physical work at 4–6 months.

Return to sport (4–6 months): High-impact activity (jogging, skiing, tennis) at 4–6 months in those with uneventful recovery. Running — controversial with THA — is more widely accepted after resurfacing in active males given the preserved bone stock and high-activity implant design intent.

Lifelong surveillance programme (MHRA/FDA requirements):

• Annual serum cobalt and chromium ion measurement — mandatory for all MoM hip patients
• MARS (metal artefact reduction sequence) MRI if: ions above threshold, new onset pain, swelling, clicking, or functional deterioration
• Clinical review at 6 weeks, 3 months, 1 year, then annually
• AP pelvis X-ray at 1 year to confirm stable fixation and component positioning; then every 3–5 years
• Revision surgery if pseudotumour, elevated ions with clinical symptoms, or component failure is confirmed

Hip resurfacing is priced similarly to or slightly higher than THA due to implant costs and technical complexity. However, international cost differences are substantial:

• United States: USD 35,000–55,000 (total episode); the procedure is less commonly performed in the US than in the UK or Australia due to historical FDA scrutiny of MoM bearings
• United Kingdom: GBP 9,000–18,000 (private); available on NHS for appropriately selected young patients; shorter waiting times than for THA at high-volume centres
• India: USD 5,000–9,000 — BHR implant imported and available at major orthopaedic centres; 75–85% savings versus US pricing; high-volume hip surgeons with resurfacing-specific training available in Mumbai, Delhi, and Chennai
• Thailand: USD 9,000–14,000 — JCI-accredited centres in Bangkok; fewer centres offering resurfacing than THA
• Germany / Austria: EUR 12,000–20,000 — centres with dedicated resurfacing programmes and high annual volumes
• Australia: AUD 15,000–25,000 (private) — high-volume centres, particularly in Melbourne and Sydney, with comprehensive registry follow-up

Key cost variables: surgeon resurfacing-specific experience (the single most important outcome predictor), implant brand (BHR vs. alternatives), inclusion of post-operative metal ion monitoring programme, and physiotherapy package. Patients travelling for resurfacing should ensure their surgeon performs at least 50+ resurfacings annually and has demonstrable BHR certification.

• Total hip replacement (THA): The primary alternative; suitable for all patients including those who are poor candidates for resurfacing (women, older patients, poor bone quality, AVN); longer track record, wider surgeon availability, and no metal ion monitoring requirement; recommended over resurfacing for women by most national guidelines
• Hip arthroscopy: Appropriate for patients with FAI or labral tears and a preserved joint space (>2 mm); cannot treat advanced arthritis; described in the companion guide
• Physiotherapy and activity modification: Effective for mild-to-moderate arthritis; delays but does not prevent arthroplasty for advanced disease
• Intra-articular corticosteroid or PRP injection: Provides temporary pain relief; appropriate while awaiting surgical planning or for patients unfit for surgery
• Periacetabular osteotomy (PAO): For hip dysplasia in younger patients with preserved cartilage; prevents arthritis development; complementary to — not a replacement for — arthroplasty in established arthritis
• Conservative pain management: NSAIDs, topical analgesics, walking aids, and weight loss; appropriate for patients who decline surgery or have prohibitive operative risk; can manage symptoms for months to years